M Aronson1, C Swallow2, A Govindarajan2, K Semotiuk1, Z Cohen1, P Kaurah3, L Velsher4, I Ambus4, K Buckley5, C Forster-Gibson6, W S Meschino7, A Blumenthal8, R H Kim9, S Brar2. 1. Sinai Health System, Zane Cohen Centre for Digestive Diseases, University of Toronto, Toronto, ON. 2. Sinai Health System, Department of Surgery, University of Toronto, Toronto, ON. 3. BC Cancer, Vancouver, BC. 4. North York General Hospital, Toronto, ON. 5. Grand River Hospital, Kitchener, ON. 6. Trillium Health Partners, Mississauga, ON. 7. Porcupine Health Unit, Timmins, ON. 8. Lakeridge Health, Oshawa, ON. 9. Sinai Health System, Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, ON.
Abstract
Background: CDH1 pathogenic variants (pvs) cause most cases of inherited diffuse gastric cancer (dgc), but have low detection rates and vary geographically. In the present study, we examined hereditary causes of dgc in patients in Ontario. Methods: CDH1 testing through single-site or multi-gene panels was conducted for patients with dgc meeting the 2015 International Gastric Cancer Linkage Consortium (igclc) criteria, or with isolated dgc at less than 50 years of age, or with a strong family history of cancer identified at the Zane Cohen Centre (zcc). All CDH1-positive patients at zcc, regardless of cancer history, were summarized. Results: In 15 of 85 patients with dgc (17.6%), a pv or likely pv was identified through CDH1 single-site (n = 43) or multi-gene panel (n = 42) testing. The detection rate was 9.4% overall (8 of 85) and 11% using igclc criteria (7 of 65). No CDH1 pvs were identified in patients with isolated dgc at less than 40 years of age, but 1 pv was identified in a patient with isolated dgc at less than 50 years of age. Multi-gene panels identified 9 pvs (21.4%), including CDH1, STK11, ATM, BRCA2, MLH1, and MSH2. Review of 81 CDH1 carriers identified 10% with dgc (median age: 48 years; range: 38-59 years); 41% were unaffected (median age: 53 years; range: 26-89 years). Observed malignancies other than dgc or lobular breast cancer (lbc) included colorectal, gynecologic, kidney or bladder, prostate, testicular, and ductal breast cancers. Lobular-breast cancer was seen only in 3 families. Conclusions: In Ontario, the detection rate of CDH1 pvs in patients with dgc was low: no pvs were identified in patients with isolated dgc at less than 40 years of age, and 1 was identified in a patient with isolated dgc at less than 50 years of age. Isolated lbc with no dgc was observed in CDH1-positive families, as were pathology-confirmed nondgc or non-lbc malignancies, which had not previously been reported. Given a phenotype that overlaps with other hereditary conditions, multi-gene panels are recommended for all patients with dgc at less than 50 years of age and for those meeting igclc criteria. 2020 Multimed Inc.
Background: CDH1 pathogenic variants (pvs) cause most cases of inherited diffuse gastric cancer (dgc), but have low detection rates and vary geographically. In the present study, we examined hereditary causes of dgc in patients in Ontario. Methods:CDH1 testing through single-site or multi-gene panels was conducted for patients with dgc meeting the 2015 International Gastric Cancer Linkage Consortium (igclc) criteria, or with isolated dgc at less than 50 years of age, or with a strong family history of cancer identified at the Zane Cohen Centre (zcc). All CDH1-positive patients at zcc, regardless of cancer history, were summarized. Results: In 15 of 85 patients with dgc (17.6%), a pv or likely pv was identified through CDH1 single-site (n = 43) or multi-gene panel (n = 42) testing. The detection rate was 9.4% overall (8 of 85) and 11% using igclc criteria (7 of 65). No CDH1 pvs were identified in patients with isolated dgc at less than 40 years of age, but 1 pv was identified in a patient with isolated dgc at less than 50 years of age. Multi-gene panels identified 9 pvs (21.4%), including CDH1, STK11, ATM, BRCA2, MLH1, and MSH2. Review of 81 CDH1 carriers identified 10% with dgc (median age: 48 years; range: 38-59 years); 41% were unaffected (median age: 53 years; range: 26-89 years). Observed malignancies other than dgc or lobular breast cancer (lbc) included colorectal, gynecologic, kidney or bladder, prostate, testicular, and ductal breast cancers. Lobular-breast cancer was seen only in 3 families. Conclusions: In Ontario, the detection rate of CDH1 pvs in patients with dgc was low: no pvs were identified in patients with isolated dgc at less than 40 years of age, and 1 was identified in a patient with isolated dgc at less than 50 years of age. Isolated lbc with no dgc was observed in CDH1-positive families, as were pathology-confirmed nondgc or non-lbc malignancies, which had not previously been reported. Given a phenotype that overlaps with other hereditary conditions, multi-gene panels are recommended for all patients with dgc at less than 50 years of age and for those meeting igclc criteria. 2020 Multimed Inc.
Authors: Michelle F Jacobs; Henry Dust; Erika Koeppe; Sandra Wong; Michael Mulholland; Eun-Young Choi; Henry Appelman; Elena M Stoffel Journal: Gastroenterology Date: 2019-03-29 Impact factor: 22.682
Authors: Samantha Hansford; Pardeep Kaurah; Hector Li-Chang; Michelle Woo; Janine Senz; Hugo Pinheiro; Kasmintan A Schrader; David F Schaeffer; Karey Shumansky; George Zogopoulos; Teresa Almeida Santos; Isabel Claro; Joana Carvalho; Cydney Nielsen; Sarah Padilla; Amy Lum; Aline Talhouk; Katie Baker-Lange; Sue Richardson; Ivy Lewis; Noralane M Lindor; Erin Pennell; Andree MacMillan; Bridget Fernandez; Gisella Keller; Henry Lynch; Sohrab P Shah; Parry Guilford; Steven Gallinger; Giovanni Corso; Franco Roviello; Carlos Caldas; Carla Oliveira; Paul D P Pharoah; David G Huntsman Journal: JAMA Oncol Date: 2015-04 Impact factor: 31.777
Authors: Namrata Setia; Jeffrey W Clark; Dan G Duda; Theodore S Hong; Eunice L Kwak; John T Mullen; Gregory Y Lauwers Journal: Oncologist Date: 2015-09-30
Authors: A Viel; M Genuardi; E Lucci-Cordisco; E Capozzi; V Rovella; M Fornasarig; M Ponz de Leòn; M Anti; M Pedroni; A Bellacosa; A Percesepe; M Covino; P Benatti; L Del Tin; L Roncucci; M Valentini; M Boiocchi; G Neri Journal: Community Genet Date: 1998
Authors: S A Gayther; K L Gorringe; S J Ramus; D Huntsman; F Roviello; N Grehan; J C Machado; E Pinto; R Seruca; K Halling; P MacLeod; S M Powell; C E Jackson; B A Ponder; C Caldas Journal: Cancer Res Date: 1998-09-15 Impact factor: 12.701
Authors: Mev Dominguez-Valentin; D Gareth R Evans; Sigve Nakken; Hélène Tubeuf; Daniel Vodak; Per Olaf Ekstrøm; Anke M Nissen; Monika Morak; Elke Holinski-Feder; Alexandra Martins; Pål Møller; Eivind Hovig Journal: Hered Cancer Clin Pract Date: 2018-01-15 Impact factor: 2.857
Authors: Tim Marwitz; Robert Hüneburg; Isabel Spier; Jan-Frederic Lau; Glen Kristiansen; Philipp Lingohr; Jörg C Kalff; Stefan Aretz; Jacob Nattermann; Christian P Strassburg Journal: Cancers (Basel) Date: 2020-12-11 Impact factor: 6.639